When Rachel Archer noticed a small pimple on her forehead, she thought nothing of it—having acne-prone skin, she was used to ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...